Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Blocked In Adding CV Claim For Januvia, May Fall Behind Victoza

Apr 07 2017

• By Joseph Haas

Clouds-Lightning-Storm_1200x675

Related Content

Jardiance Joy Boosts Boehringer Ingelheim

Apr 07 2017

Merck 1Q: Januvia meets CVOT goals; Keytruda ready to go in NSCLC

Apr 29 2015

BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim

Dec 02 2016

<em>Januvia</em> Gains Another Boost With FDA Warnings for <em>Onglyza</em>, <em>Nesina</em>

Apr 11 2016

Diabetes Drug Labels Should Reflect Heart Failure Risk, FDA Panel Says

Apr 15 2015

Sitagliptin Shows No Increased Cardiovascular Risk In Merck’s TECOS Trial

Jun 08 2015

Cardiovascular Benefits of SGLT2 Inhibitors: A Class Effect?

Mar 21 2017

Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission

Nov 04 2016

Related Companies

Merck & Co., Inc.

Boehringer Ingelheim GmbH

Eli Lilly and Company

AstraZeneca PLC

Novo Nordisk A/S

Takeda Pharmaceutical Co. Ltd.

Additional Topics

Complete Response Letters Clinical Trials Regulation Cardiovascular Metabolic Disorders BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window